Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Core Insights - Pfizer reported solid financial results for the full year 2025, with revenues of $62.6 billion, reflecting a 2% year-over-year operational decline, but a 6% operational growth excluding COVID-19 product contributions [1][2] - The company reaffirmed its financial guidance for 2026, expecting revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00 [1][2] - Pfizer's strategic focus includes approximately 20 key pivotal study starts planned for 2026, aimed at maximizing growth opportunities [1][2] Financial Performance - Full-year 2025 revenues were $62.6 billion, down from $63.6 billion in 2024, with a 2% operational decline [1][2] - Fourth-quarter 2025 revenues totaled $17.6 billion, a decrease of 1% compared to the prior year, with an operational decline of 3% [1][2] - Adjusted diluted EPS for 2025 was $3.22, reflecting a 4% increase from $3.11 in 2024 [1][2] Revenue Breakdown - The global biopharmaceuticals business saw a 2% decline in revenues for both the fourth quarter and full year [1][2] - Notable revenue growth was observed in products like Padcev (up 15%), Lorbrena (up 45%), and Abrysvo (up 136%) [1][2] - Significant declines were noted in Paxlovid (down 70%) and Comirnaty (down 35%) due to reduced COVID-19 infection rates and vaccination recommendations [1][2] Capital Allocation - In 2025, Pfizer invested approximately $8.8 billion in business development transactions and $10.4 billion in internal R&D projects [1][2] - The company returned $9.8 billion to shareholders through cash dividends, with no share repurchases completed in 2025 [1][2] - Pfizer's remaining share repurchase authorization as of February 3, 2026, is $3.3 billion, with no share repurchases anticipated in 2026 [1][2] Strategic Developments - Pfizer announced several key product developments, including positive Phase 3 results for Braftovi and Hympavzi, and advancements in its obesity treatment pipeline [2] - The company completed the acquisition of Metsera for approximately $7.0 billion, enhancing its portfolio in obesity and cardiometabolic diseases [2] - Pfizer also reached an agreement to exit its investment in ViiV Healthcare Limited for $1.875 billion [2]